Personalising pancreas cancer treatment: When tissue is the issue

The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX (fluorouracil, leucovorin, irinotecan and oxaliplatin) and nab-paclitaxel-gemcitabine have demonstrated some improved outcomes. Advances in technology espec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sjoquist, Katrin M, Chin, Venessa T, Chantrill, Lorraine A, O’Connor, Chelsie, Hemmings, Chris, Chang, David K, Chou, Angela, Pajic, Marina, Johns, Amber L, Nagrial, Adnan M, Biankin, Andrew V, Yip, Desmond
Format: Artigo
Idioma:Inglês
Publicat: Baishideng Publishing Group Inc 2014
Matèries:
Topic Highlight
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4069313/
https://ncbi.nlm.nih.gov/pubmed/24976722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i24.7849
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars